Literature DB >> 27756107

Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients.

Michael H Rivner1, Siyang Liu2, Brandy Quarles1, Brandi Fleenor1, Chengyong Shen2, Jinxiu Pan2, Lin Mei1,2.   

Abstract

INTRODUCTION: The prevalence and characteristics of agrin and low-density lipoprotein-related receptor protein 4 (LRP4) antibody-positive amyotrophic lateral sclerosis (ALS) patients were studied.
METHODS: We tested 82 ALS patients and 59 controls for agrin and LRP4 antibodies using enzyme-linked immunoassay (ELISA).
RESULTS: We found that 13.8% of ALS patients had agrin antibodies, and 9.8% had LRP4 antibodies. Women with ALS are twice as likely as men to have antibodies. Agrin-positive ALS patients are younger than agrin-negative ALS patients.
CONCLUSIONS: Antibodies to agrin and LRP4 are found in ALS patients. It must be determined whether these antibodies are pathogenic. Because antibody-positive patients have upper as well as lower motor neuron findings, the antibodies' effects cannot be explained solely by their actions at the neuromuscular junction. A breakdown in interneuronal signaling may be the cause of ALS. Further research is needed to resolve this question. Muscle Nerve, 2016 Muscle Nerve 55: 430-432, 2017.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  ALS; Agrin; LRP4; amyotrophic lateral sclerosis; antibodies; low-density lipoprotein-related receptor protein 4

Mesh:

Substances:

Year:  2016        PMID: 27756107      PMCID: PMC5318258          DOI: 10.1002/mus.25438

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  14 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Anti-agrin autoantibodies in myasthenia gravis.

Authors:  Christiane Gasperi; Arthur Melms; Benedikt Schoser; Yina Zhang; Julia Meltoranta; Valerie Risson; Laurent Schaeffer; Bertold Schalke; Stephan Kröger
Journal:  Neurology       Date:  2014-05-02       Impact factor: 9.910

3.  Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

Authors:  Osamu Higuchi; Johko Hamuro; Masakatsu Motomura; Yuji Yamanashi
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

4.  LRP4 serves as a coreceptor of agrin.

Authors:  Bin Zhang; Shiwen Luo; Qiang Wang; Tatsuo Suzuki; Wen C Xiong; Lin Mei
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

5.  LRP4 is critical for neuromuscular junction maintenance.

Authors:  Arnab Barik; Yisheng Lu; Anupama Sathyamurthy; Andrew Bowman; Chengyong Shen; Lei Li; Wen-cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2014-10-15       Impact factor: 6.167

6.  Lrp4 is a receptor for Agrin and forms a complex with MuSK.

Authors:  Natalie Kim; Amy L Stiegler; Thomas O Cameron; Peter T Hallock; Andrea M Gomez; Julie H Huang; Stevan R Hubbard; Michael L Dustin; Steven J Burden
Journal:  Cell       Date:  2008-10-09       Impact factor: 41.582

7.  Autoantibodies to agrin in myasthenia gravis patients.

Authors:  Bin Zhang; Chengyong Shen; Beverly Bealmear; Samia Ragheb; Wen-Cheng Xiong; Richard A Lewis; Robert P Lisak; Lin Mei
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

8.  LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients.

Authors:  John S Tzartos; Paraskevi Zisimopoulou; Michael Rentzos; Nikos Karandreas; Vasiliki Zouvelou; Panagiota Evangelakou; Anastasios Tsonis; Thomas Thomaidis; Giuseppe Lauria; Francesca Andreetta; Renato Mantegazza; Socrates J Tzartos
Journal:  Ann Clin Transl Neurol       Date:  2013-12-30       Impact factor: 4.511

9.  Synaptic plasticity and cognitive function are disrupted in the absence of Lrp4.

Authors:  Andrea M Gomez; Robert C Froemke; Steven J Burden
Journal:  Elife       Date:  2014-11-19       Impact factor: 8.140

Review 10.  Amyotrophic lateral sclerosis: Problems and prospects.

Authors:  Jemeen Sreedharan; Robert H Brown
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

View more
  13 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

Review 2.  Neuromuscular Junction Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Sagar Verma; Shiffali Khurana; Abhishek Vats; Bandana Sahu; Nirmal Kumar Ganguly; Pradip Chakraborti; Mandaville Gourie-Devi; Vibha Taneja
Journal:  Mol Neurobiol       Date:  2022-01-08       Impact factor: 5.590

3.  Late-onset Myasthenia Gravis Accompanied by Amyotrophic Lateral Sclerosis with Antibodies against the Acetylcholine Receptor and Low-density Lipoprotein Receptor-related Protein 4.

Authors:  Keiko Ohnari; Kazumasa Okada; Osamu Higuchi; Hidenori Matsuo; Hiroaki Adachi
Journal:  Intern Med       Date:  2018-10-15       Impact factor: 1.271

Review 4.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

5.  Presence of antibodies against low-density lipoprotein receptor-related protein 4 and impairment of neuromuscular junction in a Chinese cohort of amyotrophic lateral sclerosis.

Authors:  Lin Lei; Xin-Ming Shen; Shu-Yan Wang; Yan Lu; Suo-Bin Wang; Hai Chen; Zheng Liu; Ya-Sheng Ouyang; Jian-Ying Duo; Yu-Wei Da; Zhi-Guo Chen
Journal:  Chin Med J (Engl)       Date:  2019-06-20       Impact factor: 2.628

Review 6.  Extrachromosomal Circular DNA: Current Knowledge and Implications for CNS Aging and Neurodegeneration.

Authors:  Quratul Ain; Christian Schmeer; Diane Wengerodt; Otto W Witte; Alexandra Kretz
Journal:  Int J Mol Sci       Date:  2020-04-02       Impact factor: 5.923

7.  Sex-Specific Differences in Motor-Unit Remodeling in a Mouse Model of ALS.

Authors:  Éric Martineau; Adriana Di Polo; Christine Vande Velde; Richard Robitaille
Journal:  eNeuro       Date:  2020-02-26

Review 8.  Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 9.  Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies.

Authors:  Hans Frykman; Pankaj Kumar; Joel Oger
Journal:  Front Neurol       Date:  2020-12-09       Impact factor: 4.003

Review 10.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.